EXOZYMES INC. Proceeds from Debt, Net of Issuance Costs
EXOZYMES INC. (EXOZ) reported Proceeds from Debt, Net of Issuance Costs of $5.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-08-13
- 2026-06-30: Proceeds from Debt, Net of Issuance Costs $639.99K; Proceeds from Debt, Net of Issuance Costs 6 month $5.86M.
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 6 month |
|---|---|---|
| 2026-06-30 | $639.99K 10-Q · filed 2026-08-13 | $5.86M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |